BP will wait for proof of efficacy. that was my point. many already got burnt 1st go round. so ARWR needs to show FC rate over what IFN and Nucs provide and then you have something. till then why would BP get involved
2014 was CA fault. he was running around to all the inst investors pumping the thesis of 1 log kd being the key. they bought in, helped him do a secondary at inflated prices, and then ARWR didn't deliver. what do you expect.
CA is a BSer. honestly the pumpers here do a better job promoting the company than he does. he has lost all credibility with Inst investors
believe that is completely wrong. Roche adn NVS exited their own RNAI boondoggles and don't likley want anything more to do with it than their existing rights with ARWR. Gilead is only interested if trials produce a cure rate better than what Nucs provide.
likely partner would be another rnai co imo until their products actually cure someone of something.
CA has put the company in a precarious position needing cash before the trials pan out. bet the farm as it were. of course thats what investors wanted, so they get what they deserve either way